- Conditions
- Bullous Pemphigoid
- Interventions
- dupilumab, Matching Placebo, Oral corticosteroids (OCS)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
- Interventions
- Dupilumab - Standard Dose
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Dupilumab, Cemiplimab
- Biological
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Allergic Fungal Rhinosinusitis
- Interventions
- Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland